Company intelligence / Profile preview

Advent-Harrington Impact Fund

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

The Advent-Harrington Impact Fund is a transatlantic investment partnership supporting early- and mid-stage life sciences companies to advance breakthrough discoveries into novel treatments, with profits recycled for further research at the Harrington Discovery Institute; it completed fundraising for $215 million in 2021 and is actively investing.

Therapeutic areas: CardiovascularImmunologyWomen's HealthInfectious DiseasesNeurologyOtherOncology
Modalities: Small moleculeBiologicMedical device
Industry: Investors

Partnerships

Harrington Discovery InstituteMorgan Stanley Wealth Management (via MS GIFT Cures philanthropic partnership)British Patient CapitalRoche (Arrakis partnership - downstream)Bayer (KaNDy Therapeutics sale - downstream)

Beyond the preview

Go deeper on Advent-Harrington Impact Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advent-Harrington Impact Fund.

Explore the full profile